vs
DULUTH HOLDINGS INC.（DLTH）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是DULUTH HOLDINGS INC.的1.5倍（$168.4M vs $114.9M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -9.6%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -31.6%）
德卢思控股是一家美国工装及配饰企业，主打通过旗下德卢思贸易品牌开展产品销售业务，面向市场推出各类实用工装及相关配饰产品，是美国本土颇具特色的服饰零售企业。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
DLTH vs ESPR — 直观对比
营收规模更大
ESPR
是对方的1.5倍
$114.9M
营收增速更快
ESPR
高出153.3%
-9.6%
两年增速更快
ESPR
近两年复合增速
-31.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.9M | $168.4M |
| 净利润 | $-10.1M | — |
| 毛利率 | 53.8% | — |
| 营业利润率 | -7.7% | 50.6% |
| 净利率 | -8.8% | — |
| 营收同比 | -9.6% | 143.7% |
| 净利润同比 | 64.6% | — |
| 每股收益（稀释后） | $-0.29 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLTHESPR
| Q4 25 | $114.9M | $168.4M | ||
| Q3 25 | $131.7M | $87.3M | ||
| Q2 25 | $102.7M | $82.4M | ||
| Q1 25 | $241.3M | $65.0M | ||
| Q4 24 | $127.1M | $69.1M | ||
| Q3 24 | $141.6M | $51.6M | ||
| Q2 24 | $116.7M | $73.8M | ||
| Q1 24 | $245.6M | $137.7M |
净利润DLTHESPR
| Q4 25 | $-10.1M | — | ||
| Q3 25 | $1.3M | $-31.3M | ||
| Q2 25 | $-15.3M | $-12.7M | ||
| Q1 25 | $-5.6M | $-40.5M | ||
| Q4 24 | $-28.2M | — | ||
| Q3 24 | $-2.0M | $-29.5M | ||
| Q2 24 | $-7.9M | $-61.9M | ||
| Q1 24 | $6.4M | $61.0M |
毛利率DLTHESPR
| Q4 25 | 53.8% | — | ||
| Q3 25 | 54.7% | — | ||
| Q2 25 | 52.0% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 52.3% | — | ||
| Q3 24 | 52.3% | — | ||
| Q2 24 | 52.8% | — | ||
| Q1 24 | 48.2% | — |
营业利润率DLTHESPR
| Q4 25 | -7.7% | 50.6% | ||
| Q3 25 | 1.8% | -11.4% | ||
| Q2 25 | -12.0% | 8.6% | ||
| Q1 25 | -1.8% | -34.0% | ||
| Q4 24 | -17.4% | -6.4% | ||
| Q3 24 | -1.1% | -31.0% | ||
| Q2 24 | -7.7% | 3.5% | ||
| Q1 24 | 3.6% | 52.5% |
净利率DLTHESPR
| Q4 25 | -8.8% | — | ||
| Q3 25 | 1.0% | -35.9% | ||
| Q2 25 | -14.9% | -15.4% | ||
| Q1 25 | -2.3% | -62.2% | ||
| Q4 24 | -22.2% | — | ||
| Q3 24 | -1.4% | -57.2% | ||
| Q2 24 | -6.7% | -83.9% | ||
| Q1 24 | 2.6% | 44.3% |
每股收益（稀释后）DLTHESPR
| Q4 25 | $-0.29 | $0.32 | ||
| Q3 25 | $0.04 | $-0.16 | ||
| Q2 25 | $-0.45 | $-0.06 | ||
| Q1 25 | $-0.17 | $-0.21 | ||
| Q4 24 | $-0.84 | $-0.14 | ||
| Q3 24 | $-0.06 | $-0.15 | ||
| Q2 24 | $-0.24 | $-0.33 | ||
| Q1 24 | $0.20 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.2M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $160.6M | $-302.0M |
| 总资产 | $468.0M | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DLTHESPR
| Q4 25 | $8.2M | $167.9M | ||
| Q3 25 | $5.7M | $92.4M | ||
| Q2 25 | $8.6M | $86.1M | ||
| Q1 25 | $3.3M | $114.6M | ||
| Q4 24 | $9.3M | $144.8M | ||
| Q3 24 | $9.8M | $144.7M | ||
| Q2 24 | $6.8M | $189.3M | ||
| Q1 24 | $32.2M | $226.6M |
股东权益DLTHESPR
| Q4 25 | $160.6M | $-302.0M | ||
| Q3 25 | $170.0M | $-451.4M | ||
| Q2 25 | $167.9M | $-433.5M | ||
| Q1 25 | $182.7M | $-426.2M | ||
| Q4 24 | $188.1M | $-388.7M | ||
| Q3 24 | $215.7M | $-370.2M | ||
| Q2 24 | $218.4M | $-344.2M | ||
| Q1 24 | $222.8M | $-294.3M |
总资产DLTHESPR
| Q4 25 | $468.0M | $465.9M | ||
| Q3 25 | $433.8M | $364.0M | ||
| Q2 25 | $463.7M | $347.1M | ||
| Q1 25 | $452.4M | $324.0M | ||
| Q4 24 | $533.1M | $343.8M | ||
| Q3 24 | $488.6M | $314.1M | ||
| Q2 24 | $471.4M | $352.3M | ||
| Q1 24 | $491.2M | $373.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.7M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | — |
| 自由现金流率自由现金流/营收 | -7.8% | — |
| 资本支出强度资本支出/营收 | 2.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.7M | — |
8季度趋势，按日历期对齐
经营现金流DLTHESPR
| Q4 25 | $-6.7M | $45.2M | ||
| Q3 25 | $32.0M | $-4.3M | ||
| Q2 25 | $-56.5M | $-31.4M | ||
| Q1 25 | $41.2M | $-22.6M | ||
| Q4 24 | $-41.1M | $-35.0M | ||
| Q3 24 | $16.6M | $-35.3M | ||
| Q2 24 | $-33.7M | $-7.2M | ||
| Q1 24 | $69.7M | $53.8M |
自由现金流DLTHESPR
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $-57.8M | — | ||
| Q1 25 | $38.7M | — | ||
| Q4 24 | $-43.7M | — | ||
| Q3 24 | $15.0M | $-35.5M | ||
| Q2 24 | $-35.2M | $-7.3M | ||
| Q1 24 | $60.6M | $53.8M |
自由现金流率DLTHESPR
| Q4 25 | -7.8% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | -56.3% | — | ||
| Q1 25 | 16.0% | — | ||
| Q4 24 | -34.4% | — | ||
| Q3 24 | 10.6% | -68.7% | ||
| Q2 24 | -30.2% | -9.9% | ||
| Q1 24 | 24.7% | 39.0% |
资本支出强度DLTHESPR
| Q4 25 | 2.0% | 0.0% | ||
| Q3 25 | 1.7% | 0.0% | ||
| Q2 25 | 1.3% | 0.0% | ||
| Q1 25 | 1.0% | 0.0% | ||
| Q4 24 | 2.1% | 0.0% | ||
| Q3 24 | 1.2% | 0.3% | ||
| Q2 24 | 1.3% | 0.1% | ||
| Q1 24 | 3.7% | 0.1% |
现金转化率DLTHESPR
| Q4 25 | — | — | ||
| Q3 25 | 25.40× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.86× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLTH
| Sales Channel Directly To Consumer | $67.4M | 59% |
| Sales Channel Through Intermediary | $47.4M | 41% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
